148 related articles for article (PubMed ID: 31564372)
1. PCSK9-D374Y mediated LDL-R degradation can be functionally inhibited by EGF-A and truncated EGF-A peptides: An in vitro study.
Valenti V; Noto D; Giammanco A; Fayer F; Spina R; Altieri GI; Ingrassia V; Scrimali C; Barbagallo CM; Brucato F; Misiano G; Cefalù AB; Averna MR
Atherosclerosis; 2020 Jan; 292():209-214. PubMed ID: 31564372
[TBL] [Abstract][Full Text] [Related]
2. PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide.
Shan L; Pang L; Zhang R; Murgolo NJ; Lan H; Hedrick JA
Biochem Biophys Res Commun; 2008 Oct; 375(1):69-73. PubMed ID: 18675252
[TBL] [Abstract][Full Text] [Related]
3. Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation.
Zhang DW; Lagace TA; Garuti R; Zhao Z; McDonald M; Horton JD; Cohen JC; Hobbs HH
J Biol Chem; 2007 Jun; 282(25):18602-18612. PubMed ID: 17452316
[TBL] [Abstract][Full Text] [Related]
4. First Food-Derived Peptide Inhibitor of the Protein-Protein Interaction between Gain-of-Function PCSK9
Grazioso G; Bollati C; Sgrignani J; Arnoldi A; Lammi C
J Agric Food Chem; 2018 Oct; 66(40):10552-10557. PubMed ID: 30226051
[TBL] [Abstract][Full Text] [Related]
5. Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9.
Jang HD; Lee SE; Yang J; Lee HC; Shin D; Lee H; Lee J; Jin S; Kim S; Lee SJ; You J; Park HW; Nam KY; Lee SH; Park SW; Kim JS; Kim SY; Kwon YW; Kwak SH; Yang HM; Kim HS
Eur Heart J; 2020 Jan; 41(2):239-252. PubMed ID: 31419281
[TBL] [Abstract][Full Text] [Related]
6. Low-density lipoprotein receptor activity in Epstein-Barr virus-transformed lymphocytes from heterozygotes for the D374Y mutation in the PCSK9 gene.
Holla ØL; Cameron J; Berge KE; Kulseth MA; Ranheim T; Leren TP
Scand J Clin Lab Invest; 2006; 66(4):317-28. PubMed ID: 16777760
[TBL] [Abstract][Full Text] [Related]
7. LDL-R promoting activity of peptides derived from human PCSK9 catalytic domain (153-421): design, synthesis and biochemical evaluation.
Alghamdi RH; O'Reilly P; Lu C; Gomes J; Lagace TA; Basak A
Eur J Med Chem; 2015 Mar; 92():890-907. PubMed ID: 25679794
[TBL] [Abstract][Full Text] [Related]
8. Degradation of the LDL receptors by PCSK9 is not mediated by a secreted protein acted upon by PCSK9 extracellularly.
Holla ØL; Cameron J; Berge KE; Ranheim T; Leren TP
BMC Cell Biol; 2007 Mar; 8():9. PubMed ID: 17328821
[TBL] [Abstract][Full Text] [Related]
9. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
Urban D; Pöss J; Böhm M; Laufs U
J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
[TBL] [Abstract][Full Text] [Related]
10. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Single Domain Antibodies Are Potent Inhibitors of Low Density Lipoprotein Receptor Degradation.
Weider E; Susan-Resiga D; Essalmani R; Hamelin J; Asselin MC; Nimesh S; Ashraf Y; Wycoff KL; Zhang J; Prat A; Seidah NG
J Biol Chem; 2016 Aug; 291(32):16659-71. PubMed ID: 27284008
[TBL] [Abstract][Full Text] [Related]
11. Characterization of the role of EGF-A of low density lipoprotein receptor in PCSK9 binding.
Gu HM; Adijiang A; Mah M; Zhang DW
J Lipid Res; 2013 Dec; 54(12):3345-57. PubMed ID: 24103783
[TBL] [Abstract][Full Text] [Related]
12. Effect of mutations in the PCSK9 gene on the cell surface LDL receptors.
Cameron J; Holla ØL; Ranheim T; Kulseth MA; Berge KE; Leren TP
Hum Mol Genet; 2006 May; 15(9):1551-8. PubMed ID: 16571601
[TBL] [Abstract][Full Text] [Related]
13. Lupin Peptide T9 (GQEQSHQDEGVIVR) Modulates the Mutant PCSK9
Lammi C; Bollati C; Lecca D; Abbracchio MP; Arnoldi A
Nutrients; 2019 Jul; 11(7):. PubMed ID: 31330826
[TBL] [Abstract][Full Text] [Related]
14. Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor.
Zhang DW; Garuti R; Tang WJ; Cohen JC; Hobbs HH
Proc Natl Acad Sci U S A; 2008 Sep; 105(35):13045-50. PubMed ID: 18753623
[TBL] [Abstract][Full Text] [Related]
15. A chimeric LDL receptor containing the cytoplasmic domain of the transferrin receptor is degraded by PCSK9.
Holla ØL; Strøm TB; Cameron J; Berge KE; Leren TP
Mol Genet Metab; 2010 Feb; 99(2):149-56. PubMed ID: 19828345
[TBL] [Abstract][Full Text] [Related]
16. Internalized PCSK9 dissociates from recycling LDL receptors in PCSK9-resistant SV-589 fibroblasts.
Nguyen MA; Kosenko T; Lagace TA
J Lipid Res; 2014 Feb; 55(2):266-75. PubMed ID: 24296664
[TBL] [Abstract][Full Text] [Related]
17. Molecular basis for LDL receptor recognition by PCSK9.
Kwon HJ; Lagace TA; McNutt MC; Horton JD; Deisenhofer J
Proc Natl Acad Sci U S A; 2008 Feb; 105(6):1820-5. PubMed ID: 18250299
[TBL] [Abstract][Full Text] [Related]
18. In silico Screening of Chemical Libraries to Develop Inhibitors That Hamper the Interaction of PCSK9 with the LDL Receptor.
Min DK; Lee HS; Lee N; Lee CJ; Song HJ; Yang GE; Yoon D; Park SW
Yonsei Med J; 2015 Sep; 56(5):1251-7. PubMed ID: 26256967
[TBL] [Abstract][Full Text] [Related]
19. Antagonism of secreted PCSK9 increases low density lipoprotein receptor expression in HepG2 cells.
McNutt MC; Kwon HJ; Chen C; Chen JR; Horton JD; Lagace TA
J Biol Chem; 2009 Apr; 284(16):10561-70. PubMed ID: 19224862
[TBL] [Abstract][Full Text] [Related]
20. Degradation of LDLR protein mediated by 'gain of function' PCSK9 mutants in normal and ARH cells.
Fasano T; Sun XM; Patel DD; Soutar AK
Atherosclerosis; 2009 Mar; 203(1):166-71. PubMed ID: 19081568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]